Inside Drug Pricing - 05/13/2019

Progressive Views Of Arbitration Color Drug-Pricing Debate

By Rachel Cohrs John Wilkerson / May 7, 2019 at 2:16 PM
Progressive Democrats have made clear they do not want an arbiter to mediate disputes between drug makers and Medicare over drug prices, but their opposition to arbitration goes beyond the pharmaceutical space. Negative associations with forced arbitration in other contexts have cemented progressives’ opposition to an arbitration-based drug-pricing policy being pushed by one of House Speaker Nancy Pelosi’s (D-CA) top aides. Congressional Progressive Caucus Co-Chair Rep. Pramila Jayapal (D-WA) said her distrust of forced arbitration in other contexts, including sexual...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.